Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis

Shanghai Changzheng Hospital200 enrolled

Overview

The aim of this study is to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis.

Chronic hepatitis B is one of the most widespread viral infections worldwide, potentially leading to liver cirrhosis and hepatocellular carcinoma. Previous studies demonstrated that patients with active viral replication, defined as the presence of detectable serum HBV-DNA or HBeAg, were at increased risk of developing progressive liver disease or death.The prognosis of decompensated cirrhosis resulting from chronic hepatitis B virus infection is poor. Anti-viral therapy in decompensated HBV-related cirrhosis has been recommended by the American Association for the Study of Liver Diseases. However, no high quality research on the effectiveness of anti-viral therapy in decompensated cirrhosis has been performed. Entecavir is a new nucleotide analogue, which has been proved effective in suppressing viral replication and decreasing the necroinflammatory response, was recommended as a first-line medication in AASLD guideline. Our purpose was to evaluate the effect of Entecavir for patients With decompensated HBV-Related cirrhosis. The main outcomes were liver function, HBV-DNA, disease progression, hepatocellular carcinoma, Child-Pugh score and the survival.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

Hepatitis B Virus Decompensated Cirrhosis

Interventions

EntecavirDRUG

Entecavir 0.5 mg/d

Eligibility

Sex: ALLMin age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. over 16 years of age; 2. evidence of active viral replication was documented by a positive test for HBV-DNA in serum; 3. Liver cirrhosis was proven by ultrasound or CT; 4. Decompensated cirrhosis was evidenced by a Child-Pugh score ≥ 7; 5. patients had decompensation signs such as jaundice, ascites, variceal bleeding, hepatic encephalopathy Exclusion Criteria: 1. evidence of hepatocellular carcinoma (suspicious foci on hepatic ultrasonography at screening or a rising serum level of alpha-fetoprotein) 2. a serum alanine aminotransferase level more than 10 times the upper limit of normal 3. coinfection with hepatitis C or D virus or human immunodeficiency virus 4. other types of cirrhosis 5. a history of anti-viral therapy 6. a total bilirubin level higher than 170 mmol/L 7. a history of malignant tumors

Locations (1)

Shanghai changzheng Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

liver function

Time frame: 1 year

HBV-DNA

Time frame: 1 year

Secondary Outcomes

disease progression

Time frame: 2 years

hepatocellular carcinoma

Time frame: 2 year

Child-Pugh score

Time frame: 2 year

motality

Time frame: 2 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.